Efficacy and Safety of Daprodustat Vs rhEPO for Anemia in Patients With Chronic Kidney Disease: A Meta-Analysis and Trial Sequential Analysis

Introduction: Daprodustat, a novel hypoxia-inducible factor prolyl-hydroxylase inhibitor (HIF-PHI), its efficacy and safety remain unclear. Thus, we conducted this meta-analysis aiming at investigating its efficacy and safety on the treatment of patients with chronic kidney disease (CKD)-related ane...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Zhangning, Geng, Xiaodong, Chi, Kun, Song, Chengcheng, Wu, Di, Liu, Chao, Hong, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961323/
https://www.ncbi.nlm.nih.gov/pubmed/35359863
http://dx.doi.org/10.3389/fphar.2022.746265

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961323/
https://www.ncbi.nlm.nih.gov/pubmed/35359863
http://dx.doi.org/10.3389/fphar.2022.746265

Ejemplares similares